Últimas noticias sobre Lucid Group (NASDAQ:LCID) Bolsa

Lucid Group

Lucid Gr

Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations and through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.

Xpeng, Hesai Group, Kohl's, Groupon, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Equities

News

Markets

$BTC

DOMH

LCID

MRNA

NVDA

TSLA

El mercado bursátil de Estados Unidos enfrentó una jornada complicada ayer, ya que el sentimiento de riesgo continuó bajo presión en Wall Street. El índice S&amp;P 500 vivió una sesión volátil, alcanzando su punto más bajo en más de seis meses antes de recuperar parte de sus pérdidas.

Nvidia, Moderna, Lucid, Dominari, Tesla: 5 acciones que están en el radar de los inversores

CAVA

FSLR

SMCI

El mercado cerró con movimientos mixtos: algunas acciones sorprendieron con subidas, mientras que otras registraron fuertes caídas.

Tesla, First Solar, Cava, Lucid y Super Micro Computer: 5 acciones que están en el radar de los inversores

Tech

Media

BYDDF

BYDDY

MSFT

RIVN

XIACF

XIACY

Nvidia presenta su supercomputadora de IA Proyecto DIGITS y GPU RTX 5000 en el CES 2025, destacando colaboraciones con Meta y Toyota.

Nvidia brilla en el CES 2025 con Proyecto DIGITS y colaboraciones estratégicas

Lucid Group Inc

&nbsp;LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) (the "Company"), a provider of personal emergency response systems (PERS), health communication devices, and technology for the growing care economy, today announced changes to its Board committee assignments.
The LogicMark Board of Directors maintains an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee. The Board comprises four independent non-executive directors who serve on the Committees and the Company's Chief Executive Officer (CEO), totaling five directors.
The following new Board committee assignments reflect LogicMark's ongoing efforts to ensure that its Board effectively supports the Company's strategic direction and operational footprint.
Key updates include:
Carine Schneider, a director since October 2023, has been appointed Board Chair and remains a member of the Compensation Committee. She has helped grow B2B companies across multiple channels within capital markets, SaaS providers, and advisory services, utilizing AI and blockchain technology. She is the former President of Nasdaq Private Market and CEO of SaaS company Certent.
John Pettitt, who has served as a Director since March 2022, has been appointed Chair of the Nominating and Corporate Governance Committee. He continues to serve as a member of the Audit and Compensation Committees. John is a technology leader at Google with deep software and e-commerce expertise and a seasoned entrepreneur, having founded, edited, and IPO'd several companies.
Robert Curtis, a Director since July 2018, has been named Chair of the Compensation Committee, supported by Directors Schneider and Pettitt. He will continue to serve on the Audit Committee. He is a seasoned life sciences executive and strategic advisor with over 30 years of experience leading biotech and healthcare organizations, specializing in early-stage company development, scientific innovation, and strategic growth.
Barbara Gutierrez was appointed to the Board in May 2022 and remains Chair of the Audit Committee and is the Board's designated financial expert. She is a Certified Public Accountant and Chartered Management Accountant. Directors Pettitt and Curtis support her on the Audit Committee. Barbara is the CFO of Nasdaq-listed Modivcare and a highly accomplished board advisor with 30+ years of experience leading IPOs, complex financings, and growth strategies for public companies across the healthcare and technology sectors.
Chia-Lin Simmons, CEO of LogicMark and executive Board member since June 2021, continues to lead the Company's daily operations and does not serve on Board committees in line with governance best practices. Her extensive experience includes 30 years in the technology industry, including executive roles at Google, Audible / Amazon, and Harman International, and founding AI startup LookyLoo, reflecting her deep expertise in AI, IoT, and SaaS.
Carine Schneider, Board Chair, commented, "It's an honor to continue serving as part of the LogicMark Board as we help shape the Company's evolution into a leading-edge technology platform. This transformation, driven by our strategic focus on AI and machine learning, the launch of groundbreaking solutions like the Freedom Alert Max and the Aster App, and the value of our growing patent portfolio comprising 37 patents, 23 of which have been issued, and 17 currently filed since 2021, reflect our commitment to innovation and impact. As we redefine the customer experience and deepen our presence in the growing care economy, LogicMark is poised to thrive in the promising future of connected care." &nbsp;

Management

LGMK

LogicMark Announces Changes To Board

American Healthcare REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHR#NYSE">AHR</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $35.4, a high estimate of $37.00, and a low estimate of $34.00. Observing a 4.89% increase, the current average has risen from the previous average price target of $33.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1745845265_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive American Healthcare REIT is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joe Dickstein &#x7C;Jefferies &#x7C;Announces &#x7C;Buy &#x7C; $37.00&#x7C;- &#x7C; 
&#x7C;Austin Wurschmidt &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $34.00&#x7C;$35.00 &#x7C; 
&#x7C;Ronald Kamdem &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $37.00&#x7C;$36.00 &#x7C; 
&#x7C;Michael Carroll &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $34.00&#x7C;$34.00 &#x7C; 
&#x7C;Aaron Hecht &#x7C;Citizens Capital Markets&#x7C;Raises &#x7C;Market Outperform&#x7C; $35.00&#x7C;$30.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to American Healthcare REIT. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of American Healthcare REIT compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for American Healthcare REIT's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of American Healthcare REIT's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AHR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on American Healthcare REIT analyst ratings.</a>
<h2>Delving into American Healthcare REIT's Background</h2>
American Healthcare REIT Inc is a healthcare-focused real estate investment trust. It owns a diversified portfolio of clinical healthcare real estate properties, focusing on medical office buildings, skilled nursing facilities, senior housing, hospitals, and other healthcare-related facilities. It has four reportable business segments: integrated senior health campuses, outpatient medical, triple-net leased properties and SHOP. It generates majority of its revenue through Integrated Senior Health Campuses segment.
<h3>Understanding the Numbers: American Healthcare REIT's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: American Healthcare REIT displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 12.47%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: American Healthcare REIT's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -5.85%, the company may face hurdles in effective cost management.
Return on Equity (ROE): American Healthcare REIT's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -1.42%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): American Healthcare REIT's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.69%, the company may face hurdles in achieving optimal financial performance.
Debt Management: American Healthcare REIT's debt-to-equity ratio is below the industry average at 0.83, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What Analysts Are Saying About American Healthcare REIT Stock

In the last three months, 7 analysts have published ratings on Kontoor Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Kontoor Brands and provided 12-month price targets. The average target is $89.71, accompanied by a high estimate of $108.00 and a low estimate of $69.00. This current average represents a 9.12% decrease from the previous average price target of $98.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1745845256_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Kontoor Brands. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Paul Kearney &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $69.00&#x7C;$93.00 &#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $72.00&#x7C;$83.00 &#x7C; 
&#x7C;Ike Boruchow &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $90.00&#x7C;$100.00 &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $96.00&#x7C;$108.00 &#x7C; 
&#x7C;Paul Kearney &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $93.00&#x7C;$100.00 &#x7C; 
&#x7C;Ike Boruchow &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $100.00&#x7C;$95.00 &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $108.00&#x7C;$112.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Kontoor Brands. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kontoor Brands compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Kontoor Brands's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Kontoor Brands's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KTB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kontoor Brands analyst ratings.</a>
<h2>About Kontoor Brands</h2>
Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. The Company has two reportable segments: Wrangler and Lee. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
<h3>Kontoor Brands: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Kontoor Brands showcased positive performance, achieving a revenue growth rate of 4.4% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Kontoor Brands's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.15%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 16.9%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Kontoor Brands's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.87%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.98.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Kontoor Brands: Insights From 7 Financial Analysts

Across the recent three months, 7 analysts have shared their insights on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $59.57, with a high estimate of $80.00 and a low estimate of $36.00. Highlighting a 11.42% decrease, the current average has fallen from the previous average price target of $67.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1745845243_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Celldex Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Edward Nash &#x7C;Canaccord Genuity &#x7C;Announces &#x7C;Buy &#x7C; $64.00&#x7C;- &#x7C; 
&#x7C;Judah Frommer &#x7C;Morgan Stanley &#x7C;Announces &#x7C;Overweight &#x7C; $46.00&#x7C;- &#x7C; 
&#x7C;Richard Law &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $36.00&#x7C;$42.00 &#x7C; 
&#x7C;Joseph Pantginis &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $80.00&#x7C;$80.00 &#x7C; 
&#x7C;Joseph Pantginis &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $80.00&#x7C;$80.00 &#x7C; 
&#x7C;Trung Huynh &#x7C;UBS &#x7C;Announces &#x7C;Buy &#x7C; $44.00&#x7C;- &#x7C; 
&#x7C;Kristen Kluska &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Overweight &#x7C; $67.00&#x7C;$67.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celldex Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celldex Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Celldex Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Celldex Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CLDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Celldex Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Celldex Therapeutics</h2>
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
<h3>Celldex Therapeutics's Economic Impact: An Analysis</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Celldex Therapeutics's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -71.56%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -4007.83%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Celldex Therapeutics's ROE excels beyond industry benchmarks, reaching -6.14%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Celldex Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.83%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Celldex Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLDX

Analyst Expectations For Celldex Therapeutics's Future

MicroAlgo's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NYSE">MLGO</a>) short percent of float has fallen 50.52% since its last report. The company recently reported that it has 2.07 million shares sold short, which is 21.09% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>MicroAlgo Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745845229_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for MicroAlgo has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing MicroAlgo's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, MicroAlgo's peer group average for short interest as a percentage of float is 3.88%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

MLGO

How Do Investors Really Feel About MicroAlgo?

In the preceding three months, 19 analysts have released ratings for Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">12</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Comcast and provided 12-month price targets. The average target is $40.37, accompanied by a high estimate of $55.00 and a low estimate of $31.00. Highlighting a 11.99% decrease, the current average has fallen from the previous average price target of $45.87. 
<img src="https://www.benzinga.com/files/images/story/2025/1745845229_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Comcast by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Barton Crockett &#x7C;Rosenblatt &#x7C;Maintains &#x7C;Neutral &#x7C; $36.00&#x7C;$36.00 &#x7C; 
&#x7C;Maher Yaghi &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Perform &#x7C; $44.50&#x7C;$45.00 &#x7C; 
&#x7C;Timothy Horan &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $38.00&#x7C;$55.00 &#x7C; 
&#x7C;Michael Rollins &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $39.00&#x7C;$44.00 &#x7C; 
&#x7C;Bradley Thomas &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $45.00&#x7C;$47.00 &#x7C; 
&#x7C;Steven Cahall &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Underweight &#x7C; $31.00&#x7C;$37.00 &#x7C; 
&#x7C;Maher Yaghi &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Perform &#x7C; $45.00&#x7C;$44.50 &#x7C; 
&#x7C;John Hodulik &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $40.00&#x7C;$47.00 &#x7C; 
&#x7C;Barton Crockett &#x7C;Rosenblatt &#x7C;Lowers &#x7C;Neutral &#x7C; $36.00&#x7C;$45.00 &#x7C; 
&#x7C;Kannan Venkateshwar &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $37.00&#x7C;$42.00 &#x7C; 
&#x7C;Maher Yaghi &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Perform &#x7C; $44.50&#x7C;$48.00 &#x7C; 
&#x7C;Michael Rollins &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $44.00&#x7C;$47.00 &#x7C; 
&#x7C;Sebastiano Petti &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $39.00&#x7C;$45.00 &#x7C; 
&#x7C;Tim Nollen &#x7C;Macquarie &#x7C;Lowers &#x7C;Neutral &#x7C; $36.00&#x7C;$42.00 &#x7C; 
&#x7C;Matthew Harrison &#x7C;Benchmark &#x7C;Lowers &#x7C;Buy &#x7C; $55.00&#x7C;$57.00 &#x7C; 
&#x7C;Steven Cahall &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $37.00&#x7C;$45.00 &#x7C; 
&#x7C;Benjamin Swinburne &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $38.00&#x7C;$45.00 &#x7C; 
&#x7C;Jessica Reif Cohen &#x7C;B of A Securities &#x7C;Lowers &#x7C;Neutral &#x7C; $38.00&#x7C;$50.00 &#x7C; 
&#x7C;Michael Ng &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $44.00&#x7C;$50.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Comcast. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Comcast compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Comcast's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Comcast's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CMCSA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Comcast analyst ratings.</a>
<h2>Unveiling the Story Behind Comcast</h2>
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to 64 million US homes and businesses, or nearly half of the country. About 50% of the locations in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC network, the Peacock streaming platform, several local NBC affiliates, Universal Studios, and several theme parks. The firm plans to spin off most of its cable networks later in 2025. Finally, Sky, acquired in 2018, is a large television provider in the UK and Italy, and it also has a presence in Germany and Austria.
<h3>Breaking Down Comcast's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Comcast's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -0.57%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: Comcast's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.29% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Comcast's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.92%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Comcast's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.26%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.14.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CMCSA

Where Comcast Stands With Analysts

Plains All American's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NYSE">PAA</a>) short percent of float has risen 5.64% since its last report. The company recently reported that it has 9.59 million shares sold short, which is 2.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Plains All American Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745845224_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Plains All American has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Plains All American's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Plains All American's peer group average for short interest as a percentage of float is 3.42%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Plains All American?

In the last three months, 4 analysts have published ratings on Carter's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $41.75, a high estimate of $49.00, and a low estimate of $25.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 27.18%. 
<img src="https://www.benzinga.com/files/images/story/2025/1745845219_0_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Carter's. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Paul Kearney &#x7C;Barclays &#x7C;Announces &#x7C;Underweight &#x7C; $25.00&#x7C;- &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $49.00&#x7C;$57.00 &#x7C; 
&#x7C;Paul Lejuez &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $45.00&#x7C;$50.00 &#x7C; 
&#x7C;Ike Boruchow &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $48.00&#x7C;$65.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Carter's. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Carter's compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Carter's's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Carter's's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CRI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Carter's analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Carter's Better</h2>
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.
<h3>Carter's's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Carter's's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 0.22%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Carter's's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.01%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.15%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Carter's's ROA stands out, surpassing industry averages. With an impressive ROA of 2.5%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Carter's's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.32.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Carter's Through 4 Analysts

Mirion Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MIR#NYSE">MIR</a>) short percent of float has risen 9.0% since its last report. The company recently reported that it has 6.48 million shares sold short, which is 3.15% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.96 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Mirion Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745845219_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Mirion Technologies has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Mirion Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Mirion Technologies's peer group average for short interest as a percentage of float is 8.76%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Mirion Technologies?

During the last three months, 11 analysts shared their evaluations of Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Macy's and provided 12-month price targets. The average target is $13.73, accompanied by a high estimate of $17.00 and a low estimate of $8.00. Highlighting a 11.42% decrease, the current average has fallen from the previous average price target of $15.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1745845212_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Macy's by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Paul Kearney &#x7C;Barclays &#x7C;Announces &#x7C;Equal-Weight &#x7C; $12.00&#x7C;- &#x7C; 
&#x7C;Brooke Roach &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $12.00&#x7C;$17.00 &#x7C; 
&#x7C;Paul Lejuez &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $11.00&#x7C;$14.00 &#x7C; 
&#x7C;Matthew Boss &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $13.00&#x7C;$14.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $15.00&#x7C;$15.00 &#x7C; 
&#x7C;Paul Lejuez &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $14.00&#x7C;$16.00 &#x7C; 
&#x7C;Brooke Roach &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $17.00&#x7C;$19.00 &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Lowers &#x7C;Sell &#x7C; $8.00&#x7C;$9.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Lowers &#x7C;Market Perform &#x7C; $15.00&#x7C;$17.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $17.00&#x7C;$17.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $17.00&#x7C;$17.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Macy's. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Macy's compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Macy's's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Macy's's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/M/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Macy's analyst ratings.</a>
<h2>Get to Know Macy's Better</h2>
Founded in 1858 and based in New York City, Macy's operates about 450 stores under the Macy's nameplate, nearly 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's nameplates, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constitute about 62% of Macy's sales.
<h3>Unraveling the Financial Story of Macy's</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Macy's's revenue growth over a period of 3M has faced challenges. As of 31 January, 2025, the company experienced a revenue decline of approximately -4.39%. This indicates a decrease in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Macy's's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.27% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.86%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Macy's's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.03% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Macy's's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.25.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Macy's: Insights From 11 Analyst Reviews

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan analyst Jeffrey Zekaukas downgraded the rating for Eastman Chemical Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) from Overweight to Neutral and lowered the price target from $112 to $76. Eastman Chemical shares closed at $75.84 on Friday. <a href="https://www.benzinga.com/quote/EMN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Tejas Savant downgraded Avantor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) from Overweight to Equal-Weight and slashed the price target from $25 to $15. Avantor shares closed at $12.93 on Friday. <a href="https://www.benzinga.com/quote/AVTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC analyst Rajesh Kumar downgraded the rating for Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) from Buy to Reduce and lowered the price target from $1,150 to $700. Eli Lilly shares closed at $884.54 on Friday. <a href="https://www.benzinga.com/quote/LLY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Javier Martinez downgraded Adecoagro S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>) from Equal-Weight to Underweight and cut the price target from $13 to $10. Adecoagro shares closed at $9.92 on Friday. <a href="https://www.benzinga.com/quote/AGRO/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying LLY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28085854/image-196-1024x593.png" alt="" class="wp-image-890906" style="width:532px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28085854/image-196-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28085854/image-196-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28085854/image-196-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28085854/image-196.png 1125w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

AGRO

AVTR

This Eli Lilly Analyst Turns Bearish; Here Are Top 4 Downgrades For Monday

STSSW

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

On April 24, 2025, iShares MSCI Argentina and Global Exposure ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARGT#NYSE">ARGT</a>) dashed ahead of leading indices, making even the S&amp;P 500 and the popular iShares MSCI Emerging Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEM#NYSE">EEM</a>) nervously trying to catch up.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44706269/argentinas-congress-approves-investigation-of-scam-ridden-libra-token-promoted-by-president-javier-milei">Argentina&#8217;s Congress Approves Investigation Of Scam-Ridden LIBRA Token Promoted By President Javier Milei</a>
As reported by <a href="https://www.benzinga.com/topic/eric-balchunas">Bloomberg analyst Eric Balchunas</a>, ARGT closed at $42.35, a steep 3.5% daily advance from its earlier close of $40.90. In comparison, the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose just 0.5% to $498.12, and the Emerging Markets ETF, a broader indicator of emerging countries, managed a 1.2% gain, closing at $43.70.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">TIL The Argentina ETF has been absolutely destroying <a href="https://twitter.com/search?q=%24SPY&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SPY</a> and EM (altho that isn&#39;t that hard).. wow <a href="https://twitter.com/search?q=%24ARGT&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ARGT</a> <a href="https://t.co/S7GBs64yrS">pic.twitter.com/S7GBs64yrS</a>
&mdash; Eric Balchunas (@EricBalchunas) <a href="https://twitter.com/EricBalchunas/status/1915394943587098962?ref_src=twsrc%5Etfw">April 24, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
So, what&#8217;s driving this Latin rally? Argentina&#8217;s recent move to relax long-standing currency controls has ignited investor enthusiasm. The government&#8217;s action was an appreciated tango step toward liberalization, drawing capital inflows and prompting a surge in equity demand, Blockchain News <a href="https://blockchain.news/flashnews/argentina-etf-outperforms-spy-and-emerging-markets-a-trading-analysis">said</a>. 
Also Read:<a href="https://www.benzinga.com/markets/equities/25/03/44568118/is-us-taking-cues-from-argentinas-bold-reforms-that-sparked-a-market-rally"> Is US Taking Cues From Argentina&#8217;s Bold Reforms That Sparked A Market Rally?</a>
ARGT Vs EEM: Apples And Empanadas
While EEM provides diversified exposure across nations such as China, India, Brazil and South Korea, ARGT is far more focused, following the MSCI All Argentina 25/50 Index, which concentrates on the top 20 Argentine firms. That makes ARGT riskier but also more responsive to domestic economic reform, a risk and an opportunity. ARGT places a heavy weight on local players like MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), YPF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YPF#NYSE">YPF</a>), and Grupo Financiero Galicia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGAL#NASDAQ">GGAL</a>), giving it a high beta.
EEM, on the other hand, leans toward Chinese tech giants like Tencent (OTCPK: TCEHY) and Alibaba (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), as well as those from South Korea and India. This insulates the fund from country-specific shocks. But as a tradeoff, the upside is less explosive when a single market surges.
Additionally, ARGT levies a bit higher fee of 59 basis points compared to EEM&#8217;s 68 bps but provides a more focused bet on a single recovering market.
For those with a taste for measured risk and a preference for macro-fueled momentum, ARGT may be the spicier dish to try. As EEM continues to offer a well-balanced, globally diversified option, ARGT&#8217;s high-conviction exposure to Argentina&#8217;s liberalizing economy offers a high-reward option, along with a side of risk. As Buenos Aires opens the throttle and investor enthusiasm warms up, ARGT may remain a popular choice.
Read Next: 
<a href="https://www.benzinga.com/etfs/sector-etfs/25/04/45020234/forget-nvidia-etfs-are-quietly-piling-into-amd-do-they-know-something-we-dont">Forget Nvidia, ETFs Are Quietly Piling Into AMD — Do They Know Something We Don&#8217;t?</a>
Photo: Shutterstock

Sector ETFs

Specialty ETFs

ETFs

ARGT

BABA

GGAL

MELI

TCEHY

ARGT Vs EEM: Why Argentina's Focused ETF Is Gaining The Edge

Transaction Enables Sabre to Pay Down Debt, Optimize Portfolio, and Continue Its Focus on&nbsp;Sustainable Growth
Transaction Will Establish Hospitality Solutions Business as an Independent Technology Company Built for the Hospitality Industry &nbsp;
SOUTHLAKE, Texas, April 28, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4414213-1&amp;h=3579934675&amp;u=http%3A%2F%2Fwww.sabre.com%2F&amp;a=Sabre+Corporation">Sabre Corporation</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>), a leading technology provider to the global travel industry,&nbsp;and TPG, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>), a global alternative asset management firm, today announced the signing of a definitive agreement under which TPG has agreed to acquire Sabre's Hospitality Solutions business ("Hospitality Solutions") for $1.1 billion in cash. TPG will invest in Hospitality Solutions through TPG Capital, the firm's U.S. and European private equity platform.
Sabre's expected cash proceeds, net of taxes and fees, of approximately $960 million, will be used primarily to pay down debt, enabling Sabre to improve its balance sheet, optimize focus on its core business, and continue its focus on long-term sustainable growth.
In addition to the purchase agreement described above, the parties expect to enter into a transition services agreement, pursuant to which Sabre will provide certain services following closing to assist in the transition of the Hospitality Solutions business. The transaction has been approved by Sabre Corporation's Board of Directors and is expected to close by the end of the third quarter 2025, subject to customary closing conditions and regulatory approvals. The closing of the transaction is not subject to any financing conditions.
 &nbsp;

SABR

TPG Agrees To Acquire Sabre's Hospitality Solutions Business For $1.1B In Cash

Barclays analyst David Anderson maintains Oceaneering International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>) with a Equal-Weight and lowers the price target from $22 to $21.

Price Target

Barclays Maintains Equal-Weight on Oceaneering International, Lowers Price Target to $21

President Donald Trump&#8216;s support for a tax increase on millionaires, a move that has sparked controversy and political debate among Republicans and conservatives.
What Happened:&nbsp;In a discussion with&nbsp;Time magazine&nbsp;on Tuesday, Trump revealed his inclination towards increasing&nbsp;the marginal tax rate for&nbsp;those earning more than a million dollars per year. This viewpoint has sparked outrage&nbsp;among traditional conservatives and business&nbsp;circles, while some of Trump&#8217;s congressional allies have shown a willingness to consider the idea, contingent on Trump&#8217;s endorsement, reported <a href="https://thehill.com/business/domestic-taxes/5268494-trump-millionaires-tax-idea/">The Hill</a> on Monday.
Grover Norquist, president of Americans for Tax Reform, vehemently opposed the proposal, labeling it a &#8220;really bad idea&#8221; and asserting that it &#8220;ain&#8217;t happening.&#8221; He cited former President George H.W. Bush&#8216;s political downfall following his broken "Read my lips: No new taxes&#8221; pledge as a warning for Trump, as it could result in &#8216;Political Death.&#8217;
A Republican strategist told The Hill, "I think it would be very disruptive, because a lot of the millionaires would leave the country&#8230;You lose a lot of money if you do that." 
Senate Republicans are warning that the budget reconciliation package, which aims to secure borders, expand domestic energy production, increase defense spending, and extend the 2017 tax cuts, will not pass if it raises the tax rate on the top income bracket or introduces a new tax bracket for those earning over $1 million annually.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/45003759/arks-bitcoin-bear-case-is-300000-by-2030-whats-the-bull-case" target="_blank" rel="noreferrer noopener">ARK&#8217;s Bitcoin &#8216;Bear Case&#8217; Is $300,000 By 2030—What&#8217;s The Bull Case? &#8211; Benzinga</a>
Why It Matters:&nbsp;Trump&#8217;s comments come on the heels of an interview, where he expressed potential support for a<a href="https://www.benzinga.com/25/04/45026565/trump-signals-possible-support-for-millionaires-tax-amid-election-concerns-recalls-george-bushs-promise-he-said-read-my-lips-and-lost-an-election"> millionaires&#8217; tax</a>, citing concerns about its impact on his electoral chances. The President also rejected the claim that raising taxes on the wealthy to provide more tax relief for working-class Americans would amount to a tax hike.
Despite the criticism, Trump stood by his stance, stating his intent to increase taxes on the wealthy to provide more tax relief for the working class. However, he also voiced concerns about the political repercussions of such a move, referencing past electoral defeats linked to tax hikes.
This move also follows a <a href="https://www.benzinga.com/25/04/44831978/senator-josh-hawley-proposes-historic-tax-cuts-for-americans-earning-below-80k-annually-republicans-should-fix-this-now">proposal </a>by U.S. Senator Josh Hawley for a substantial tax cut for Americans earning less than $80,000 annually. The various proposals highlight the ongoing debate on tax reform and its implications for different income groups.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/45034209/bitcoin-could-hit-120000-in-q2-says-standard-chartereds-geoff-kendrick" target="_blank" rel="noreferrer noopener">Bitcoin Could Hit $120,000 In Q2, Says Standard Chartered&#8217;s Geoff Kendrick &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump's Proposed Millionaires Tax Draws Fierce GOP Pushback: 'Doing So Would Be Political Death,' Experts Caution

SuperCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>) reported quarterly earnings of $0.66 per share which beat the analyst consensus estimate of $(0.46) by 243.48 percent. This is a 78 percent decrease over earnings of $3.00 per share from the same period last year. The company reported quarterly sales of $6.33 million which missed the analyst consensus estimate of $6.48 million by 2.38 percent. This is a 11.63 percent increase over sales of $5.67 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

SPCB

SuperCom Q4 Adj. EPS $0.66 Beats $(0.46) Estimate, Sales $6.33M Miss $6.48M Estimate

STSS

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

STKH

XFOR

Commodities

Press Releases

Lucid Gravity Now Available to Configure and Order for Customers in Canada on the Lucid Motors Website

Small Cap

Lucid Announces CEO Transition

Lucid Announces Fourth Quarter and Full Year 2024 Financial Results

Lucid Announces Q1 Production & Deliveries, Sets Date for First Quarter 2025 Results

Offerings

Lucid Group, Inc. Announces Proposed Convertible Senior Notes Offering

Lucid Group, Inc. Prices $1,000,000,000 Convertible Senior Notes Offering

Lucid Group, Inc. Announces Closing of Private Offering of $1.1 Billion of Convertible Senior Notes Due 2030

Lucid to Acquire Select Facilities and Assets Previously Belonging to Nikola Corporation, Will Extend Offers to 300+ Former Nikola Employees

Introducing the 2026 Lucid Gravity Grand Touring: A Force of Attraction Like Nothing Else in Nature

GraniteShares 2x Long LCID Daily ETF (LCDL) and GraniteShares 2x Long RIVN Daily ETF (RVNL) Launch Today.

LCDL

RVNL

AYRO

Cenntro

Chijet Motor Company, Inc. - Ordinary Shares

Chijet Motor Co

ECD Automotive Design, Inc. - Common Stock

ECD Automotive Design

Envirotech Vehicles

Ford Motor

Faraday Future Intelligent Electric Inc. - Class A Common Stock

Faraday Future

Fly-E Group

General Motors

Honda Motor Co

Li Auto Inc. - American Depositary Shares

Li Auto

Lotus Technology Inc. - American Depositary Shares

Lotus Technology

NIO Inc. American depositary shares, each representing one Class A ordinary share

NWTN

Polestar Automotive Holding UK Limited - Class A ADS

Polestar Automotive

Polestar Automotive Holding UK Limited - Class C-1 ADS (ADW)

Rivian Automotive, Inc. - Class A Common Stock

Rivian Automotive

Thor Industries

Toyota Motor

Tesla

VinFast Auto

Winnebago Industries

Workhorse Gr

XPeng Inc. American depositary shares, each representing two Class A ordinary shares

XPeng

ZEEKR Intelligent Technology Holding Limited American Depositary Shares (each representing ten (10) Ordinary Shares)

Comments

Lucid Group

Noticias

Últimas noticias sobre Lucid Group (NASDAQ:LCID) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL